drugset / Trial / NCT00920725
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Timeline
- Start
- 2005-01
- Primary completion
- 2007-07
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Insulin | Protein / enzyme biologic | 0.1 iu/kg | Intravenous |
| Comparator | insulin aspart | Protein / enzyme biologic | 0.1 iu/kg | Subcutaneous |
| Comparator | insulin aspart | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |